Genelabs Regains Exclusive Rights to Prestara in Japan

Genelabs Technologies has regained full development and licensing rights in Japan for its investigational lupus drug Prestara under the terms of a termination agreement with Mitsubishi Tanabe Pharma.

Genelabs and Japan’s Tanabe Seiyaku signed the agreement in January 2004, which stipulated that Tanabe was responsible for conducting all development work and obtaining regulatory approval for Prestara in Japan. Mitsubishi Tanabe Pharma was formed by the merger of Tanabe Seiyaku and Mitsubishi Pharma Oct. 1.

Under the terms of the agreement, no payments are to be made by either party, Genelabs said.